Drug intelligence / Profile preview

NDH001

Development stage: Preclinical
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules

Overview

NDH001 is an investigational small molecule drug candidate developed by Apichope Pharmaceutical (Guangzhou Apichope Pharmaceutical). It is currently in the preclinical stage of development for the treatment of cardiovascular and cerebrovascular diseases. As an innovative drug candidate within Apichope's pipeline, NDH001 is designed to address unmet medical needs in vascular health, although its specific biological target and molecular mechanism of action have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on NDH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDH001.

Explore the full profile